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The control of lung inflammation is of paramount importance in a variety of acute pathologies, such as
pneumonia, the acute respiratory distress syndrome, and sepsis. It is becoming increasingly apparent that local
innate immune responses in the lung are negatively influenced by systemic inflammation. This is thought to be
due to a local deficit in cytokine responses by alveolar macrophages and neutrophils following systemic
bacterial infection and the development of a septic response. Recently, using an adenovirus-based strategy
which overexpresses the human elastase inhibitor elafin locally in the lung, we showed that elafin is able to
prime lung innate immune responses. In this study, we generated a novel transgenic mouse strain expressing
human elafin and studied its response to bacterial lipopolysaccharide (LPS) when the LPS was administered
locally in the lungs and systemically. When LPS was delivered to the lungs, we found that mice expressing elafin
had lower serum-to-bronchoalveolar lavage ratios of proinflammatory cytokines, including tumor necrosis
factor alpha (TNF-), macrophage inflammatory protein 2, and monocyte chemoattractant protein 1, than
wild-type mice. There was a concomitant increase in inflammatory cell influx, showing that there was potential
priming of innate responses in the lungs. When LPS was given systemically, the mice expressing elafin had
reduced levels of serum TNF- compared to the levels in wild-type mice. These results indicate that elafin may
have a dual function, promoting up-regulation of local lung innate immunity while simultaneously down-
regulating potentially unwanted systemic inflammatory responses in the circulation.
The regulation of inflammatory cytokines and cell influx of
neutrophils and macrophages is important in a variety of lung
and systemic pathologies, such as acute respiratory distress
syndrome, pneumonia, and sepsis (11, 22, 25, 44). Recent stud-
ies have highlighted the importance of cytokine-chemokine
gradients between the alveolar space and the blood compart-
ments in influencing the outcome of lung and systemic inflam-
mations (3, 43). Such studies have shown that in rats concom-
itant lung administration and systemic administration of
bacterial lipopolysaccharide (LPS) resulted in a reduction in
the inflammatory cell influx in the alveolar space compared to
the influx in animals treated only via the pulmonary route
because of a reduced lung-blood chemotactic gradient. In re-
lated studies, it was shown that endotoxemic rats and mice with
experimentally induced bacterial pneumonia have a poor out-
come, possibly because of a lack of pulmonary neutrophilic
migration and clearance of organisms (8, 28, 46).
Of interest in this context are low-molecular-weight mucosal
elastase inhibitors, such as secretory leukocyte protease inhib-
itor (SLPI) and elafin/elastase-specific inhibitor (34, 35). These
agents have been shown to be induced by early wave cytokines,
such as interleukin-1 and tumor necrosis factor (TNF) (32),
and to have antimicrobial properties (17, 36, 37, 47). Their
concentrations are very low in blood, and they are not ex-
pressed in the liver (1, 20, 27, 29).
Recently, it has been shown that a transient overexpression
approach in which adenovirus is used as a gene vector is effi-
cient for delivering human elafin (driven by the powerful
mouse cytomegalovirus [MCMV] promoter) to mouse lung
tissues (37, 38). In addition, it was found that in mice there was
an increase in inflammatory cell migration to airways in re-
sponse to intratracheally instilled bacterial LPS (38), suggest-
ing that this inhibitor may be important as a chemoattractant
and in the priming of innate responses in lung cells.
Because lung-targeted adenovirus protocols give rise to lung
compartmentalization of transgene expression (49) and hence
only local elafin expression in the previously described model
(37), we decided to create transgenic mice expressing human
elafin more ubiquitously in order to have coexistent local ex-
pression and systemic expression of elafin. To do this, a mouse
transgenic line expressing human elafin cDNA under control
of the MCMV promoter was generated, and its characteristics
were assessed in two self-limiting models of inflammation, first
by using intratracheally instilled bacterial LPS (akin to the
method used in the adenovirus study mentioned above) and
second by using a systemic LPS administration protocol.
MATERIALS AND METHODS
Generation of transgenic mice expressing human elafin cDNA under control
of the MCMV promoter. A 6.3-kb fragment containing the elafin cDNA fragment
under control of the MCMV promoter was isolated from the PDK6 plasmid (33)
and used for microinjection. This elafin cDNA codes for the full-length elafin
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molecule, which contains transglutamination sites thought to be important for
the binding of the molecule to the intertitium (27, 29, 33).
Transgenic mice were generated by a standard protocol (18) by injecting linear
DNA (5 ng/l) into the male pronuclei of fertilized ova derived from C57BL6 
CBA F1 females. Injected ova at the two-cell stage were transferred to the
oviducts of surrogate pseudopregnant CD1 females, where development was
allowed to progress to term. One founder line was identified (see below) which
transmitted the elafin cDNA transgene under control of the MCMV promoter to
its offspring in Mendelian fashion. The transgenic line was then bred to homozy-
gosity. The number of elafin transgene copies was determined by standard
methods. Briefly, the intensity (as determined by Phosphorimager analysis) of
HindIII-digested genomic DNA was compared with the intensities of spiked
known amounts of elafin cDNA. The numbers of copies were determined by
using the following equation: 1 copy of transgene  0.538(3.78  106 g)  2
pg of genomic DNA.
The wild-type controls used had the same mixed background (C57BL6CBA)
as the transgenic mice expressing elafin.
All results described for the wild-type and transgenic mice expressing elafin
were obtained with F2 generation mice.
Southern genomic analysis. Transgenic mice were identified by Southern blot
analysis of DNA samples isolated from tail biopsies by using standard proce-
dures. Briefly, tail DNA samples were extracted with phenol-chloroform follow-
ing proteinase K digestion overnight. The resulting DNA was subsequently
precipitated with ethanol. Genomic DNA samples (10 g) were digested with
HindIII, resolved on a 1% agarose gel, and transferred in 0.4 N NaOH to a
GeneScreen Plus nylon membrane (NEN-Dupont, Stevenage, Hertsfordshire,
United Kingdom). The filter was then hybridized with a 32P-labeled random
primer-labeled human elafin cDNA probe. Prehybridization (1 h) and hybrid-
ization (overnight) were performed in 0.5 M Na2HPO4 (pH 7)–1 mM EDTA–7%
sodium dodecyl sulfate at 65°C. The filter was washed twice in 0.04 M
Na2HPO4–1% sodium dodecyl sulfate at 65°C for 30 min and exposed for
autoradiography, typically overnight.
RNA preparation and Northern blot analysis. Tissues were harvested from
adult (8-week-old) female mice. Total RNA from various murine tissues was
prepared with the Trizol reagent used according to the manufacturer’s instruc-
tions (Gibco BRL, Paisley, United Kingdom). Total RNA (20 g) was resolved
on a 1% agarose–1.7 M formaldehyde gel, transferred overnight in 20 SSC to
a Zetaprobe membrane (Bio-Rad, Hemel Hempstead, Hertfordshire, United
Kingdom), and then baked at 80°C for 1 to 2 h (1 SSC is 0.15 M NaCl plus 0.015
M sodium citrate). The filter was prehybridized, hybridized, and washed as
described above for the Southern analysis but at 55°C instead of 65°C. The filter
was exposed for autoradiography for 1 week.
DNase treatment of RNA templates. To eliminate the possibility of genomic
DNA contamination, RNA samples prepared from murine tissues or macro-
phages were digested with RQ1 RNase-free DNase I (Promega, Southampton,
United Kingdom) used in accordance with the manufacturer’s instructions prior
to use in a reverse transcription-PCR (RT-PCR) (see below).
RT-PCR and Southern analysis. Total RNA isolated from a variety of mouse
tissues (0.35 g) and peritoneal macrophages was used as the template for
first-strand cDNA synthesis. Oligonucleotide primers (MWG-Biotech, Milton
Keynes, United Kingdom) were designed to amplify a 477-bp fragment of the
elafin transcript. The elafin primers were sense primer 5 GCAGCTTCTTGAT
CGTGGTG 3 (starting at nucleotide 11 after the ATG start codon) and anti-
sense primer 5 GCCGTGGGCATCCTGAATGG 3 (nucleotides 467 to 486).
Primers were also designed to amplify a 258-bp fragment of murine glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) (sense primer, 487 to 506 bp;
antisense primer, 726 to 745 bp). Total RNA was incubated with 0.25 g of
oligo(dT) (Promega), 1 l of 10 PCR buffer (Promega), 100 U of Moloney
murine leukemia virus reverse transcriptase (Gibco BRL), 7 U of RNasin (Gibco
BRL), and 125 l of each deoxynucleoside triphosphate (Pharmacia, Bucking-
ham, Hertfordshire, United Kingdom) in a 10-l (total volume) reaction mix-
ture. The reaction mixture was incubated at 37°C for 45 min and then heated at
90°C for 5 min. Then 4 l of 10 PCR buffer, 80 pmol (each) of the forward and
reverse elafin primers, 8 pmol (each) of the forward and reverse GAPDH
primers, 2.5 U of Taq DNA polymerase (Promega), and enough H2O to bring the
total volume to 50 l were added to the RT reaction mixture. The reaction
mixture was subjected to 35 cycles of DNA amplification (94°C for 30 s, 60°C for
30 s, 70°C for 1 min) in a MJ Research thermocycler. The reaction mixture was
then held for 5 min at 70°C. When necessary, Southern blot analysis was per-
formed by using a standard method, when the concentrations of RT-PCR prod-
ucts were at the limit of detection by ethidium bromide gel staining.
In vivo experiments. (i) Intratracheal instillation of LPS. Female transgenic
mice expressing elafin and wild-type (WT) mice (ages, 8 to 10 weeks) were
instilled intratracheally with 50 g of Escherichia coli O127:B8 LPS, as described
previously (37). Twenty-four hours later, mice were sacrificed under anesthesia
by transection of the abdominal aorta, blood was retrieved for further serum
preparation, and the lungs and trachea were removed en bloc. A bronchoalveolar
lavage (BAL) was immediately performed with two serial instillations of 250 and
200 l of phosphate-buffered saline (PBS). Recovered BAL fluid (BALF) (typ-
ically 350 to 450 l) was centrifuged at 2,000  g for 5 min. Supernatants were
frozen at 20°C until they were used, while each cell pellet was resuspended in
100 l of PBS. Cell counting (with a hemacytometer) and cytospinning (300 rpm
for 3 min at room temperature) were performed. After cytospinning prepara-
tions were stained with Diff-quick (Dade Diagnostika, GmbH, Germany) for
analysis of differential cell counts.
(ii) Intraperitoneal instillation of LPS. Female transgenic mice expressing
elafin and WT mice (ages, 8 to 10 weeks) each received one intraperitoneal dose
of 120 g of LPS (as described above) in 100 l of PBS. Control mice were
injected with PBS alone. Serum samples were collected after 1.5 h and 24 h by
tail bleeding.
Thioglycolate challenge and culture of peritoneal macrophages. Female trans-
genic mice expressing elafin and WT mice (ages, 8 to 10 weeks) were injected
intraperitoneally with 1 ml of 4% thioglycolate broth to induce peritonitis. The
mice were sacrificed after 120 h, and peritoneal lavage performed with 5 ml of
cold PBS. The cells were pooled and washed with PBS. A total of 5  105 cells
were then cultured in 48-well plates in 1 ml of RPMI 1640 (Gibco BRL) medium
supplemented with 25 mM HEPES, 2 mM glutamine, 100 U of penicillin per ml,
100 g of streptomycin per ml, and 10% fetal bovine serum. After overnight
incubation, nonadherent cells were removed by washing with serum-free me-
dium, and all of the adherent cells were macrophages. LPS was then added at
different concentrations (0 to 5 ng/ml), and the cells were cultured for 48 h in
serum-containing medium. Each supernatant was removed and stored at 20°C
until it was used for enzyme-linked immunosorbent assay (ELISA) analysis.
ELISA. ELISA analyses to detect murine TNF alpha (TNF-), monocyte
chemotactic protein 1 (MCP-1), and macrophage inflammatory protein 2
(MIP-2) were performed by using commercially available ELISA kits (R & D
Systems, Abingdon, Oxon, United Kingdom) in accordance with the manufac-
turer’s instructions. Human elafin was measured by using an ELISA available
in-house (37). Culture supernatants from peritoneal macrophages were diluted
1:20 before ELISA analysis of cytokines. Serum samples (collected either 1.5 or
24 h after treatment) and BALFs were either not diluted or diluted fivefold in
PBS.
Statistical analysis. Normally distributed data were analyzed by the Student
unpaired t test. When data were not normally distributed, nonparametric tests
(Kruskal-Wallis and Mann-Whitney tests) were employed. Data were considered
to be statistically significantly different when the P value was 0.05.
RESULTS
Genotype analysis of transgenic mice expressing elafin
cDNA. The genotypes of mice were determined in order to
determine whether elafin cDNA was present. Tail biopsy DNA
was prepared and digested with HindIII (generation of a
562-bp fragment showed that the transgene was intact), as
described in Materials and Methods. Heterozygous F1 mice
were selected by Southern analysis and PCR. Male and female
mice heterozygous for the elafin cDNA were crossed to gen-
erate homozygous F2 animals (Fig. 1). Homozygous (/)
mice expressing elafin cDNA (referred to as elafin mice below)
were crossed to establish the mouse line expressing elafin.
Analysis (see Materials and Methods) revealed that the elafin
mice had three to five copies per genome. The WT mouse
controls used had the same mixed background (C57BL6 
CBA) as the elafin mice.
Northern blot and RT-PCR analyses of elafin mice. Figure 2
shows the tissue distribution of human elafin in elafin mice as
determined by Northern blot analysis (Fig. 2A) and RT-PCR
(Fig. 2B and C).
This analysis showed that although most tissues tested were
positive for the transgene (Fig. 2B), stomach, small intestine,
skeletal muscle, and bone tissues were the tissues in which
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elafin was most abundant (Fig. 2A). Due to their lower level of
elafin expression, blood and bone marrow samples were
treated separately (Fig. 2C). Compared to the intensity of the
elafin bands in the stomach sample (Fig. 2C, lane 5), the elafin
bands in the blood and bone marrow samples were much less
intense. In addition, PCR gave rise to at least two bands in the
bone marrow samples and eight bands in the blood sample.
The specificity of these products was therefore checked by
Southern analysis (by using elafin cDNA as a probe), and only
the 477-bp expected elafin product hybridized strongly, show-
ing that both blood and bone marrow cells expressed the elafin
cDNA transgene.
When tissues were analyzed for protein production (by
ELISA), the elafin levels were not always reliably measured,
which probably reflected the relative lack of sensitivity of the
assay (data not shown).
Inflammatory responses to intratracheally instilled bacte-
rial LPS. (i) Cytokines. In order to assess whether elafin mice
responded differently to LPS than WT mice responded, both
groups of mice were instilled intratracheally with 50 g of LPS
(or PBS). Because of the importance of TNF- as an early
mediator of inflammation, we first measured the TNF- levels
in BALF and serum. As shown in Table 1, as expected, both
groups of LPS-treated mice had higher BALF TNF- levels
than their PBS-treated counterparts. It should be noted that
the response to LPS was largely (but not totally) compartmen-
talized in the lungs in WT mice (there was a 22-fold increase in
the TNF- level in BALF and a 1.3-fold increase in serum after
LPS treatment). There was also a trend (not statistically sig-
nificant) toward increased levels of the cytokines in BALF
from LPS-treated elafin mice compared to the levels in LPS-
treated WT mice. When the systemic levels of TNF- in serum
were examined, the elafin mice had lower levels than the WT
mice after PBS or LPS treatment, suggesting that elafin may
have a stronger systemic anti-inflammatory activity than a local
lung proinflammatory activity in these mice.
Since TNF- is an early cytokine involved in initiation of the
inflammatory response, we extended our study to two other
cytokines, MCP-1 and MIP-2, which are chemokines for mono-
cytes and neutrophils, respectively. Because of the potential
dual activity of elafin in altering the TNF- response (weakly
proinflammatory in the lung and strongly anti-inflammatory
systemically), we expressed the data as serum/BAL cytokine
ratios (Fig. 3). In accordance with the TNF- data, elafin mice
FIG. 1. Construction and identification of the elafin cDNA trans-
gene under control of the MCMV promoter. (A) Construct used to
generate transgenic mice expressing human elafin cDNA under control
of the MCMV promoter. A 1,400-bp fragment of the MCMV pro-
moter (nucleotides1336 to 36) drives expression of the elafin cDNA
(538 bp). Restriction sites for HindIII, which were used to identify the
presence of the transgene, are indicated. (B) Genomic DNA (10 g)
isolated from tail biopsies was digested with HindIII and resolved on a
1% agarose gel. The gel was transferred to a nylon membrane, and the
filter was hybridized with radiolabeled human elafin cDNA. The off-
spring from a heterozygous intercross included wild-type (/) mice
and mice heterozygous (/-) and homozygous (/) for the human
elafin cDNA transgene. The position of the 562- bp human elafin
cDNA fragment is indicated by an arrow.
FIG. 2. Expression of the human elafin cDNA transgene in female
murine tissues. (A) Northern analysis of total RNA (20 g) from lung
(L), stomach (St), large intestine (LI), small intestine (SI), skin (S),
skeletal muscle (SM), bone (B), ovary (O), uterus (U), bladder (Bl),
heart (H), spleen (Sp), brain (Br), kidney (K), liver (Li), and thymus
(Th) tissues. Ethidium bromide staining of gels prior to transfer (lower
panel) was used to check equivalent sample loading. The positions of
the 28S and 18S rRNA are indicated on the left. The filter was hybrid-
ized with the radiolabeled human elafin cDNA probe. The position of
the 800-bp band representing human elafin mRNA is indicated on the
left. Wild-type mice showed no elafin signal (data not shown), con-
firming the results of previous studies with rats (33) showing that the
human elafin probe does not cross-react with any rodent message. (B
and C) RT-PCR analysis of elafin performed with RNA (0.35 g) from
various murine tissues (B) or from blood cells and bone marrow (C).
The message for GAPDH was coamplified with elafin to standardize
its expression. A 20-l aliquot of each RT-PCR product was resolved
on a 1.5% agarose gel. The positions of the 477-bp elafin PCR and
258-bp GAPDH PCR products are indicated on the right. The posi-
tions of molecular weight markers are indicated on the left (lane M)
(1.0-kb ladder; catalog number G 5711 for panel B; Promega). The
abbreviations for the organs are the same as those described above;
trachea (Tr) and wild-type liver RNA (WT) samples also were ana-
lyzed. (C) Total blood cells from two elafin mice were obtained by
exsanguination and subsequently pooled. Bone marrow was obtained
from the same mice, and samples were treated separately for RT-PCR.
The specificity of the 477-bp elafin cDNA band (top panel) was verified
by Southern blot analysis (bottom panel). Lane M, molecular weight
markers (catalog number 15615-016; Promega); lane 1, negative con-
trol in which water was used in place of DNA; lane 2, total blood cell
elafin cDNA; lanes 3 and 4, bone marrow elafin cDNA (independent
samples); lane 5, stomach elafin cDNA.
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exhibited the same decrease in serum/BALF MCP-1 and
MIP-2 ratios as those WT mice. It should be noted that as
shown in Table 1, although a trend was observed, the transgene
did not have a significant effect on the absolute cytokine levels
in the BALF.
(ii) Inflammatory cells. The finding that elafin mice had
lower serum/BALF ratios of inflammatory cell cytokines sug-
gested that the chemokine gradient generated may have re-
sulted in an increase in the number of inflammatory cells in
BALF from elafin mice compared to the number of inflamma-
tory cells in BALF from WT mice. Figure 4 shows that as
expected, LPS induced an influx of inflammatory cells in BALF
from the two groups of mice compared to the number of cells
after the PBS treatment. In WT mice the increase consisted
mostly of neutrophils, whereas in elafin mice both the number
of neutrophils and the number of macrophages were elevated.
Indeed, when the LPS-treated groups were considered sepa-
rately, BALF from elafin mice contained more inflammatory
cells than BALF from WT mice contained.
Interestingly, although the levels of human elafin protein in
sera and BALF were very low (consistently less than 50 pg/ml)
in elafin mice and zero in WT mice, in elafin mice treated with
PBS and LPS positive correlations were found between the
levels of elafin in BALF and the levels of of TNF-, MCP-1,
and MIP-2 (Fig. 5).
When serum levels of cytokines and elafin were analyzed,
only the relationship between TNF- and elafin levels ap-
proached statistical significance (P  0.081).
Serum TNF- levels after intraperitoneal LPS administra-
tion. The in vivo experiments whose results are shown in Table
1 and Fig. 3 showed that intratracheal instillation of 50 g of
LPS did not lead to total lung compartmentalization of the
LPS stimulus in WT mice since the TNF- levels were in-
creased in the serum of these mice. Since elafin mice had lower
levels of circulating TNF- (Table 1), we hypothesized that if
elafin could down-regulate the systemic effect of LPS when
LPS is administered intratracheally, it may dampen the re-
sponses when LPS is injected systemically. Since the level of
TNF- in serum is known to increase transiently after systemic
LPS administration and TNF- is considered a major initiator
of the septic response (4–6, 13, 39, 42), we used previously
established protocols to measure TNF- immunoreactivity in
serum 1.5 and 24 h after intraperitoneal LPS injection.
Figure 6 shows that as expected, the serum TNF- levels in
WT mice were greater 1.5 h after LPS administration and
FIG. 3. Intratracheal administration of LPS decreases serum/
BALF cytokine ratios in elafin mice compared to the ratios in WT
mice. BALF and sera from elafin mice (EL) and WT mice were
obtained 24 h after PBS administration or after intratracheal admin-
istration of 50 g of LPS (see Table 1). Serum/BALF ratios were
calculated for each cytokine (TNF-, MCP-1, MIP-2) and are ex-
pressed as the median value (plus the upper interquartile). Statistical
significance is indicated as follows: one asterisk, P  0.05 compared to
the value for WT PBS; two asterisks, P  0.05 compared to the values
for WT PBS and the other linked groups. The numbers in the bars
indicate the number of animals in each group.
FIG. 4. Intratracheal administration of LPS increases the number
of inflammatory cells in BALF from elafin mice compared to the
number of inflammatory cells in BALF from WT mice. Transgenic
mice expressing elafin (EL) and WT mice received either PBS or 50 g
of LPS intratracheally (as described in the legend to Fig. 3). After 24 h,
BALF was obtained, and differential cell counting was performed by
cytospinning. The results are expressed as the median value (plus the
upper interquartile). One asterisk, P  0.05 compared to the value for
WT PBS; two asterisks, P  0.05 compared to the values for WT PBS
and the other linked groups. The numbers at the bottom indicate the
number of animals in each group.
TABLE 1. BALF and serum TNF- levels after intratracheal
LPS administrationa
Mice Treatment No. of mice
Fold increase in
TNF- in:
BALF Serum
WT PBS 3 1 1
LPS 5 22.2b 1.29
Elafin PBS 3 0.85 0.45b
LPS 7 39.1b 0.07b,c
a BALF and sera from elafin mice and WT mice were obtained 24 h after
intratracheal administration of PBS or LPS, and TNF- levels were measured by
ELISA (see Materials and Methods). Nonparametric data were expressed as fold
increases compared with the values for WT mice that received PBS (median).
Statistical significance was assessed by using the Kruskal-Wallis and Mann-
Whitney tests.
b Significantly different from the value obtained for WT mice that received
PBS (P  0.05).
c Significantly different from the value obtained for WT mice that received
LPS (P  0.05).
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returned to the baseline value within 24 h. In sera from elafin
mice, the TNF- levels were significantly lower than those in
WT mice at 1.5 h, suggesting that elafin is indeed involved in
down-regulating systemic endotoxin responses.
Ex vivo stimulation of peritoneal macrophages with LPS. As
shown in Fig. 3, the serum/BAL cytokine ratios were lower in
elafin mice than in WT mice. In addition, we showed that bone
marrow cells and blood cells were positive for the transgene
(Fig. 2C). Given the reported anti-inflammatory properties of
the related molecule SLPI in monocytes and macrophages (10,
21, 23, 26), we hypothesized that monocytes derived from ela-
fin mice would be less responsive to LPS, thereby explaining
the reduced systemic TNF- expression in vivo (Fig. 6). To
further investigate this, we isolated monocyte-derived perito-
neal macrophages 4 days after intraperitoneal thioglycolate
injection and stimulated the cells in vitro with different levels
of LPS. Figure 7 shows that peritoneal macrophages from
elafin mice produced less TNF-, MCP-1, and MIP-2 than
peritoneal macrophages from WT mice produced, and Fig. 8
shows that these cells produced elafin mRNA, as determined
by RT-PCR (the protein level was below the threshold of
detection) (data not shown).
DISCUSSION
Human neutrophil elastase inhibitors, such as alpha-1 pro-
teinase inhibitor and SLPI, have recently been used in in vivo
models as purified or recombinant proteins to modulate lung
and systemic inflammation (24, 30, 31, 40). Workers in our
laboratory are particularly interested in elafin, a more specific
neutrophil elastase inhibitor which exhibits 40% homology
with SLPI. This 10-kDa molecule is part of a four-disulfide-
core protein family which has recently been named the trappin
family (35). In addition, it has been shown that in vitro and in
vivo elafin is a cationic molecule with activity against gram-
positive and gram-negative pathogens (36, 37) and can there-
fore be considered a defensin-like molecule with a role in
innate immunity.
Recently, the use of adenovirus as a lung vector for transient
gene expression of potentially therapeutic transgenes under
control of the strong MCMV promoter allowed us to discover
FIG. 5. Correlation between BALF elafin and cytokine levels.
BALF from elafin mice instilled intratracheally with PBS or LPS (see
the legends to Fig. 3 and 4) were analyzed for elafin and cytokine
(TNF-, MCP-1, MIP-2) levels.
FIG. 6. Serum TNF- levels are lower in elafin mice following intraperitoneal LPS injection. A TNF- ELISA analysis was performed with
serum samples obtained from WT mice and elafin mice (EL) (ages, 8 to 10 weeks) either 1.5 or 24 h after intraperitoneal administration of 120
g of LPS or PBS. The numbers of mice in the groups were as follows: WT mice treated with LPS, 10 mice; elafin mice treated with LPS, 10 mice;
WT mice treated with PBS, 5 mice; and elafin mice treated with PBS, 5 mice. All data are expressed as the mean	 standard deviation. An unpaired
two-tailed Student’s t test was used to establish statistical significance between groups. The levels of TNF- in the serum of elafin mice 1.5 h after
LPS treatment were significantly less than the levels in LPS-treated WT mice (P  0.02), as indicated by the asterisk. ND, not detected.
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a new property for elafin, its chemotactic activity for lung
inflammatory cells (38).
In order to determine thoroughly the role of this molecule in
local and systemic inflammation, in the present study we used
transgenic mice that were engineered to express human elafin
constitutively under control of the same MCMV promoter.
Importantly, our elafin construct codes for the full-length
protein, which contains transglutamination-cementoin sites
(27, 29, 34, 35) thought to be important in binding of the
molecule to the interstitium. Recently, Aiba-Masago et al.
studied expression in transgenic mice of bacterial 
-galactosi-
dase driven by an MCMV promoter similar to the one used in
our study (2). These authors found that the brain, stomach,
kidney, and skeletal muscle were the major organs which ex-
pressed the transgene. Our study (Fig. 2) showed that the
stomach, small intestine, skeletal muscle, and bone are major
sites of expression. The reasons for the slight difference in the
spectrum of organs in which the transgene is expressed be-
tween the two studies are unclear, but the difference could
reflect differences in the read-outs (i.e., mRNA levels in our
study and protein levels in the study of Aiba-Masago et al.) or
differences in the chromosomal location of the transgenes.
Alternatively, our human elafin cDNA construct has a 158-bp
3 untranslated region which may contain positive or negative
regulatory binding sites which could influence the MCMV-
associated specificity of expression. Interestingly, when study-
ing endogenous expression of human elafin RNA, Nara et al.
found that in accordance with our results, stomach and small
intestine tissues were positive as determined by an RNase
FIG. 7. Peritoneal macrophages from elafin mice are hyporesponsive to LPS. Peritoneal macrophages from elafin mice and WT mice were obtained
as described in Materials and Methods. Cells (5 105cells) were then cultured in 48-well plates in 1 ml of RPMI 1640 containing 10% fetal bovine serum
with or without different LPS concentrations (0 to 5 ng/ml). After 48 h, the medium was recovered, and the concentrations of TNF-, MCP-1, and MIP-2
were determined by ELISA. An unpaired two-tailed Student’s t test was used to establish statistical significance between groups (n 3). An asterisk
indicates that a value is statistically significantly different (P  0.05) than the value obtained with the equivalent LPS dose in WT mice
FIG. 8. Elafin mRNA production by peritoneal macrophages. Peri-
toneal macrophages from elafin mice were obtained and cultured as
described in the legend to Fig. 7, except that the LPS doses were 0, 1,
and 10 ng/ml. RT-PCR for the elafin and GAPDH transcripts was
performed as described in Materials and Methods.
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protection assay (27). Using Northern blot analysis, Pfundt et
al. showed that the human tongue and pharynx (organs not
assessed in the other studies mentioned here) are strong ex-
pressers of elafin, although these workers did not study the
stomach, small intestine, skeletal muscle, and bone (29).
Although some organs expressed elafin more strongly than
other organs, it was demonstrated by using RT-PCR that all
the organs tested here were positive for expression of human
elafin in the transgenic mice. The results of this study also
confirmed the results of a previous study (33) showing that the
human elafin cDNA probe does not cross-react with any mu-
rine message.
In the second part of our study we tested whether the elafin
mice generated here were able to modulate the activity of
intratracheally instilled LPS to the same extent that was ob-
served in the adenovirus-elafin model (38).
Figure 4 shows that there was increased inflammatory cell
influx (both neutrophils and macrophages) in BALF from ela-
fin mice compared to that in WT mice following intratracheal
LPS administration. A net increase in lung chemotactic activity
is caused by chemokine gradients generated either by an in-
crease in the levels of lung chemokines or a decrease in the
levels of systemic chemokines (3, 28, 43, 46). We therefore
measured serum and BALF chemokine levels and found that
neutrophilic, monocytic cytokine, and chemokine (TNF-,
MIP-2, and MCP-1) ratios were lower in the elafin mice (Fig.
3). In addition, the cytokine levels were found to correlate with
elafin concentrations (Fig. 5). These results are qualitatively
similar to the results observed in our adenovirus study (38).
Interestingly, although as indicated above there was a trend
toward increased numbers of macrophages in BALF from mice
given adenovirus elafin intratracheally, the number of neutro-
phils prominently increased in that study. In contrast, the num-
bers of both neutrophils and macrophages were elevated in
elafin mice in the present study. The difference between the
transient adenovirus and constitutive transgenic models could
result from differential chemotactic activity due to a difference
in lung elafin expression, which was much higher in the ade-
novirus study (nanogram levels, compared with the picogram
levels in this study), the numbers of potential different recep-
tors (currently uncharacterized), and the affinities on macro-
phages and neutrophils. Alternatively, a difference in mouse
strains (pure C57BL6 mice for the adenovirus-derived exper-
iments and a mixture of CBA and C57BL6 mice for the trans-
genic mouse experiments) could also be an explanation. Re-
gardless, the results are reminiscent of those obtained with
defensins and cathelicidins; indeed, these molecules have also
been shown to have cytokine-stimulating activities (7, 41) and
chemotactic properties for a variety of cell types in vitro (for a
recent review, see reference 52). In some instances, a receptor
has been identified; human 
-defensin 2 acts via CCR6 on
immature dendritic cells and memory T cells (50), and LL37
acts via the formyl peptide receptor-like 1 on human neutro-
phils, monocytes, and T cells (51).
In addition to the in vitro studies, Zhang et al. recently
showed that when administered intratracheally to mouse lungs,
human -defensins (a mixture of -defensin 1, -defensin 2,
and -defensin 3) also induced an increased flux of inflamma-
tory cells in the alveolar space (53). Significantly, these authors
also reported increased levels of proinflammatory cytokines,
including MCP-1, and a serum-BAL cytokine gradient similar
to the one found in our study. Interestingly, chemotactic ac-
tivity of defensins has also been demonstrated in the peritoneal
cavity following Klebsiella pneumoniae infection of mice (45).
As mentioned above, the intratracheal LPS data suggested
that in elafin mice there is an elevated gradient of cytokines
across the alveolus-blood barrier. The reduced serum TNF-
levels in elafin mice after intratracheal LPS administration
(Table 1) suggests that elafin may act in this model in part by
inhibiting circulating (but not lung) LPS signaling, after partial
leakage of LPS from the lung. Indeed, following intratracheal
LPS administration, there was a trend toward increased (not
decreased) lung TNF- production in elafin mice, which would
argue in our model against spillover of TNF- from the lung
into the circulation.
The cytokine gradient generated by elafin may have a dual
function; it may promote up-regulation of innate immunity
responses in the lung compartment and simultaneous down-
regulation of inflammatory responses in the circulation. The
latter down-regulation would be akin to that caused by SLPI,
which has been shown to decrease in vitro production of proin-
flammatory mediators in human monocytes and murine mac-
rophages (10, 21, 26, 54).
In the third part of our study, to test this hypothesis, we
injected WT mice and elafin mice intraperitoneally with LPS
and measured serum TNF- levels after treatment. Figure 6
shows that the serum TNF- levels were indeed reduced in the
elafin mice. This systemic hyporesponsiveness of elafin mice
was further studied ex vivo by examining macrophage re-
sponses to LPS. Following stimulation of peritoneal macro-
phages with LPS, it was apparent that cells from elafin mice
made elafin mRNA and that LPS was able to up-regulate the
message. This up-regulation by LPS was probably due to the
presence of nuclear factor B sites within the MCMV pro-
moter, as observed previously in the adenovirus study (38). In
addition, cells from elafin mice produced less TNF-, MIP-2,
and MCP-1 than cells from WT mice produced (Fig. 7). Inter-
estingly, macrophages from elafin mice produced less TNF-
than macrophages from WT mice produced under basal (PBS)
conditions, echoing data presented in Table 1, which show that
the serum TNF- levels were lower in the former mice.
In conclusion, these are the three main findings of the pres-
ent study. (i) The elafin mice that we created expressed human
elafin mRNA in a variety of organs (Fig. 1 and 2) and ex-
pressed protein levels in the lung and serum, as assessed by
ELISA analysis. (ii) After intratracheal LPS administration,
increases in numbers of inflammatory cells in BALF and de-
creases in the serum/BALF cytokine ratios were observed in
the elafin mice compared to the values for WT mice (Table 1
and Fig. 3 and 4). In addition, the cytokine levels were corre-
lated with the elafin concentrations in BALF (Fig. 5). (iii)
Elafin mice were less responsive to LPS, as assessed in vivo,
after intraperitoneal injection of LPS and measurement of
circulating TNF- (Fig. 6) and ex vivo (with peritoneal mac-
rophages) (Fig. 7).
Because of the role of TNF- in many of the pathophysio-
logic events in sepsis (14, 15), inhibitors of the TNF- cascade
have been extensively studied (9, 10, 12, 16, 19, 21, 23, 24, 26,
48). We believe that elastase inhibitors, such as elafin, are
particularly interesting because of their small size, which allows
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better diffusion in tissues. Both in a previous adenovirus study
(38) and in the present study a decrease in blood-BALF TNF-
–chemokine gradient in mice overexpressing elafin was
found. We believe that the elafin mice should help in assessing
which of the two strategies (i.e., local application or systemic
application of elastase inhibitors) should be more beneficial in
clinical applications. As pointed out above, because of possible
differences in site expression, care should be taken to differ-
entiate the physiological effects of an endogenous protein and
the potential therapeutic effects of a transgene. We are cur-
rently pursuing this line of investigation in our laboratory and
with our clinical colleagues.
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